Researchers from Mass General Brigham and collaborators found that use of GLP-1 drugs to treat obesity more than doubled from 2022 to 2023 while rates of surgery dropped by one quarter.
Surge in GLP-1 drug use for obesity coincides with drop in bariatric surgery
- Post author:
- Post published:October 26, 2024
- Post category:uncategorized